Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 138

1.

Systems analysis reveals complex biological processes during virus infection fate decisions.

Argilaguet J, Pedragosa M, Esteve-Codina A, Riera G, Vidal E, Peligero-Cruz C, Casella V, Andreu D, Kaisho T, Bocharov G, Ludewig B, Heath S, Meyerhans A.

Genome Res. 2019 Jun;29(6):907-919. doi: 10.1101/gr.241372.118. Epub 2019 May 28.

PMID:
31138618
2.

Linking Cell Dynamics With Gene Coexpression Networks to Characterize Key Events in Chronic Virus Infections.

Pedragosa M, Riera G, Casella V, Esteve-Codina A, Steuerman Y, Seth C, Bocharov G, Heath S, Gat-Viks I, Argilaguet J, Meyerhans A.

Front Immunol. 2019 May 3;10:1002. doi: 10.3389/fimmu.2019.01002. eCollection 2019.

3.

Peptide Assembly on the Membrane Determines the HIV-1 Inhibitory Activity of Dual-Targeting Fusion Inhibitor Peptides.

Gomara MJ, Perez Y, Martinez JP, Barnadas-Rodriguez R, Schultz A, von Briesen H, Peralvarez-Marin A, Meyerhans A, Haro I.

Sci Rep. 2019 Mar 1;9(1):3257. doi: 10.1038/s41598-019-40125-4.

4.

Cancer immunotherapy of patients with HIV infection.

Gonzalez-Cao M, Martinez-Picado J, Karachaliou N, Rosell R, Meyerhans A.

Clin Transl Oncol. 2019 Jun;21(6):713-720. doi: 10.1007/s12094-018-1981-6. Epub 2018 Nov 17. Review.

PMID:
30446984
5.

Activation of viral defense signaling in cancer.

Gonzalez-Cao M, Karachaliou N, Santarpia M, Viteri S, Meyerhans A, Rosell R.

Ther Adv Med Oncol. 2018 Aug 29;10:1758835918793105. doi: 10.1177/1758835918793105. eCollection 2018. Review.

6.

Interplay between reaction and diffusion processes in governing the dynamics of virus infections.

Bocharov G, Meyerhans A, Bessonov N, Trofimchuk S, Volpert V.

J Theor Biol. 2018 Nov 14;457:221-236. doi: 10.1016/j.jtbi.2018.08.036. Epub 2018 Aug 28.

PMID:
30170043
7.

Equilibrium Model of Drug-Modulated GagPol-Embedded HIV-1 Reverse Transcriptase Dimerization to Enhance Premature Protease Activation.

Sadiq SK, Mirambeau G, Meyerhans A.

AIDS Res Hum Retroviruses. 2018 Sep;34(9):804-807. doi: 10.1089/AID.2018.0111.

PMID:
30056738
8.

HIV LTR-Driven Antisense RNA by Itself Has Regulatory Function and May Curtail Virus Reactivation From Latency.

Kobayashi-Ishihara M, Terahara K, Martinez JP, Yamagishi M, Iwabuchi R, Brander C, Ato M, Watanabe T, Meyerhans A, Tsunetsugu-Yokota Y.

Front Microbiol. 2018 May 25;9:1066. doi: 10.3389/fmicb.2018.01066. eCollection 2018.

9.

Benzyl-2-Acetamido-2-Deoxy-α-d-Galactopyranoside Increases Human Immunodeficiency Virus Replication and Viral Outgrowth Efficacy In Vitro.

Olvera A, Martinez JP, Casadellà M, Llano A, Rosás M, Mothe B, Ruiz-Riol M, Arsequell G, Valencia G, Noguera-Julian M, Paredes R, Meyerhans A, Brander C.

Front Immunol. 2018 Jan 26;8:2010. doi: 10.3389/fimmu.2017.02010. eCollection 2017.

10.

Hybrid approach to model the spatial regulation of T cell responses.

Bouchnita A, Bocharov G, Meyerhans A, Volpert V.

BMC Immunol. 2017 Jun 21;18(Suppl 1):29. doi: 10.1186/s12865-017-0205-0.

11.

The Myxobacterial Metabolite Soraphen A Inhibits HIV-1 by Reducing Virus Production and Altering Virion Composition.

Fleta-Soriano E, Smutná K, Martínez JP, Lorca Oró C, Sadiq SK, Mirambeau G, Lopez-Iglesias C, Bosch M, Pol A, Brönstrup M, Diez J, Meyerhans A.

Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e00739-17. doi: 10.1128/AAC.00739-17. Print 2017 Aug.

12.

Oligonucleotide-Lipid Conjugates Forming G-Quadruplex Structures Are Potent and Pangenotypic Hepatitis C Virus Entry Inhibitors In Vitro and Ex Vivo.

Koutsoudakis G, Paris de León A, Herrera C, Dorner M, Pérez-Vilaró G, Lyonnais S, Grijalvo S, Eritja R, Meyerhans A, Mirambeau G, Díez J.

Antimicrob Agents Chemother. 2017 Apr 24;61(5). pii: e02354-16. doi: 10.1128/AAC.02354-16. Print 2017 May.

13.

Spatiotemporal Dynamics of Virus Infection Spreading in Tissues.

Bocharov G, Meyerhans A, Bessonov N, Trofimchuk S, Volpert V.

PLoS One. 2016 Dec 20;11(12):e0168576. doi: 10.1371/journal.pone.0168576. eCollection 2016.

14.

Homeostatically Maintained Resting Naive CD4+ T Cells Resist Latent HIV Reactivation.

Tsunetsugu-Yokota Y, Kobayahi-Ishihara M, Wada Y, Terahara K, Takeyama H, Kawana-Tachikawa A, Tokunaga K, Yamagishi M, Martinez JP, Meyerhans A.

Front Microbiol. 2016 Dec 1;7:1944. eCollection 2016.

15.

Towards standardized automated immunomonitoring: an automated ELISpot assay for safe and parallelized functionality analysis of immune cells.

Neubauer JC, Sébastien I, Germann A, Müller SC, Meyerhans A, von Briesen H, Zimmermann H.

Cytotechnology. 2017 Feb;69(1):57-73. doi: 10.1007/s10616-016-0037-4. Epub 2016 Nov 28.

16.

Position effects influence HIV latency reversal.

Chen HC, Martinez JP, Zorita E, Meyerhans A, Filion GJ.

Nat Struct Mol Biol. 2017 Jan;24(1):47-54. doi: 10.1038/nsmb.3328. Epub 2016 Nov 21.

PMID:
27870832
17.

Lymphocyte Activation Dynamics Is Shaped by Hereditary Components at Chromosome Region 17q12-q21.

Carreras-Sureda A, Rubio-Moscardo F, Olvera A, Argilaguet J, Kiefer K, Mothe B, Meyerhans A, Brander C, Vicente R.

PLoS One. 2016 Nov 11;11(11):e0166414. doi: 10.1371/journal.pone.0166414. eCollection 2016.

18.

Human DDX3 protein is a valuable target to develop broad spectrum antiviral agents.

Brai A, Fazi R, Tintori C, Zamperini C, Bugli F, Sanguinetti M, Stigliano E, Esté J, Badia R, Franco S, Martinez MA, Martinez JP, Meyerhans A, Saladini F, Zazzi M, Garbelli A, Maga G, Botta M.

Proc Natl Acad Sci U S A. 2016 May 10;113(19):5388-93. doi: 10.1073/pnas.1522987113. Epub 2016 Apr 26.

19.

Detection of Broadly Neutralizing Activity within the First Months of HIV-1 Infection.

Sanchez-Merino V, Fabra-Garcia A, Gonzalez N, Nicolas D, Merino-Mansilla A, Manzardo C, Ambrosioni J, Schultz A, Meyerhans A, Mascola JR, Gatell JM, Alcami J, Miro JM, Yuste E.

J Virol. 2016 May 12;90(11):5231-5245. doi: 10.1128/JVI.00049-16. Print 2016 Jun 1.

20.

Calcineurin and mTOR inhibitors have opposing effects on regulatory T cells while reducing regulatory B cell populations in kidney transplant recipients.

Latorre I, Esteve-Sole A, Redondo D, Giest S, Argilaguet J, Alvarez S, Peligero C, Forstmann I, Crespo M, Pascual J, Meyerhans A.

Transpl Immunol. 2016 Mar;35:1-6. doi: 10.1016/j.trim.2016.01.004. Epub 2016 Feb 1.

PMID:
26836476
21.

Pan-genotypic Hepatitis C Virus Inhibition by Natural Products Derived from the Wild Egyptian Artichoke.

Elsebai MF, Koutsoudakis G, Saludes V, Pérez-Vilaró G, Turpeinen A, Mattila S, Pirttilä AM, Fontaine-Vive F, Mehiri M, Meyerhans A, Diez J.

J Virol. 2015 Dec 9;90(4):1918-30. doi: 10.1128/JVI.02030-15. Print 2016 Feb 15.

22.

PD-L1 Blockade Differentially Impacts Regulatory T Cells from HIV-Infected Individuals Depending on Plasma Viremia.

Peligero C, Argilaguet J, Güerri-Fernandez R, Torres B, Ligero C, Colomer P, Plana M, Knobel H, García F, Meyerhans A.

PLoS Pathog. 2015 Dec 3;11(12):e1005270. doi: 10.1371/journal.ppat.1005270. eCollection 2015 Dec.

23.

Low Seroprevalence of West Nile Virus in Blood Donors from Catalonia, Spain.

Piron M, Plasencia A, Fleta-Soriano E, Martinez A, Martinez JP, Torner N, Sauleda S, Meyerhans A, Escalé J, Trilla A, Pumarola T, Martinez MJ.

Vector Borne Zoonotic Dis. 2015 Dec;15(12):782-4. doi: 10.1089/vbz.2015.1787. Epub 2015 Nov 18.

24.

Understanding Experimental LCMV Infection of Mice: The Role of Mathematical Models.

Bocharov G, Argilaguet J, Meyerhans A.

J Immunol Res. 2015;2015:739706. doi: 10.1155/2015/739706. Epub 2015 Oct 21. Review.

25.

Soraphen A: A broad-spectrum antiviral natural product with potent anti-hepatitis C virus activity.

Koutsoudakis G, Romero-Brey I, Berger C, Pérez-Vilaró G, Monteiro Perin P, Vondran FW, Kalesse M, Harmrolfs K, Müller R, Martinez JP, Pietschmann T, Bartenschlager R, Brönstrup M, Meyerhans A, Díez J.

J Hepatol. 2015 Oct;63(4):813-21. doi: 10.1016/j.jhep.2015.06.002. Epub 2015 Jun 10.

PMID:
26070407
26.

A novel whole-blood miRNA signature for a rapid diagnosis of pulmonary tuberculosis.

Latorre I, Leidinger P, Backes C, Domínguez J, de Souza-Galvão ML, Maldonado J, Prat C, Ruiz-Manzano J, Sánchez F, Casas I, Keller A, von Briesen H, Knobel H, Meese E, Meyerhans A.

Eur Respir J. 2015 Apr;45(4):1173-6. doi: 10.1183/09031936.00221514. Epub 2015 Feb 5. No abstract available.

27.

Immune screening identifies novel T cell targets encoded by antisense reading frames of HIV-1.

Berger CT, Llano A, Carlson JM, Brumme ZL, Brockman MA, Cedeño S, Harrigan PR, Kaufmann DE, Heckerman D, Meyerhans A, Brander C.

J Virol. 2015 Apr;89(7):4015-9. doi: 10.1128/JVI.03435-14. Epub 2015 Jan 14.

28.

Antiviral drug discovery: broad-spectrum drugs from nature.

Martinez JP, Sasse F, Brönstrup M, Diez J, Meyerhans A.

Nat Prod Rep. 2015 Jan;32(1):29-48. doi: 10.1039/c4np00085d. Review.

PMID:
25315648
29.

The myxobacterial metabolite ratjadone A inhibits HIV infection by blocking the Rev/CRM1-mediated nuclear export pathway.

Fleta-Soriano E, Martinez JP, Hinkelmann B, Gerth K, Washausen P, Diez J, Frank R, Sasse F, Meyerhans A.

Microb Cell Fact. 2014 Jan 29;13:17. doi: 10.1186/1475-2859-13-17.

30.

Screening of small molecules affecting mammalian P-body assembly uncovers links with diverse intracellular processes and organelle physiology.

Martínez JP, Pérez-Vilaró G, Muthukumar Y, Scheller N, Hirsch T, Diestel R, Steinmetz H, Jansen R, Frank R, Sasse F, Meyerhans A, Díez J.

RNA Biol. 2013 Nov;10(11):1661-9. doi: 10.4161/rna.26851.

31.

Identification of myxobacteria-derived HIV inhibitors by a high-throughput two-step infectivity assay.

Martinez JP, Hinkelmann B, Fleta-Soriano E, Steinmetz H, Jansen R, Diez J, Frank R, Sasse F, Meyerhans A.

Microb Cell Fact. 2013 Sep 24;12:85. doi: 10.1186/1475-2859-12-85.

32.

A novel statistical analysis and interpretation of flow cytometry data.

Banks HT, Kapraun DF, Thompson WC, Peligero C, Argilaguet J, Meyerhans A.

J Biol Dyn. 2013;7:96-132. doi: 10.1080/17513758.2013.812753.

33.

Pathogenesis and treatment of HIV infection: the cellular, the immune system and the neuroendocrine systems perspective.

Chereshnev VA, Bocharov G, Bazhan S, Bachmetyev B, Gainova I, Likhoshvai V, Argilaguet JM, Martinez JP, Rump JA, Mothe B, Brander C, Meyerhans A.

Int Rev Immunol. 2013 Jun;32(3):282-306. doi: 10.3109/08830185.2013.779375. Epub 2013 Apr 25. Review.

PMID:
23617796
34.

A division-dependent compartmental model for computing cell numbers in CFSE-based lymphocyte proliferation assays.

Banks HT, Thompson WC, Peligero C, Giest S, Argilaguet J, Meyerhans A.

Math Biosci Eng. 2012 Oct;9(4):699-736. doi: 10.3934/mbe.2012.9.699.

35.

An automated HIV-1 Env-pseudotyped virus production for global HIV vaccine trials.

Schultz A, Koch S, Fuss M, Mazzotta AS, Sarzotti-Kelsoe M, Ozaki DA, Montefiori DC, von Briesen H, Zimmermann H, Meyerhans A.

PLoS One. 2012;7(12):e51715. doi: 10.1371/journal.pone.0051715. Epub 2012 Dec 27.

36.

Targeting antibody responses to the membrane proximal external region of the envelope glycoprotein of human immunodeficiency virus.

Kamdem Toukam D, Tenbusch M, Stang A, Temchura V, Storcksdieck Genannt Bonsmann M, Grewe B, Koch S, Meyerhans A, Nchinda G, Kaptue L, Uberla K.

PLoS One. 2012;7(5):e38068. doi: 10.1371/journal.pone.0038068. Epub 2012 May 30.

37.

Aetheramides A and B, potent HIV-inhibitory depsipeptides from a myxobacterium of the new genus "Aetherobacter".

Plaza A, Garcia R, Bifulco G, Martinez JP, Hüttel S, Sasse F, Meyerhans A, Stadler M, Müller R.

Org Lett. 2012 Jun 1;14(11):2854-7. doi: 10.1021/ol3011002. Epub 2012 May 22.

PMID:
22616796
38.

Quantification of unintegrated HIV-1 DNA at the single cell level in vivo.

Suspène R, Meyerhans A.

PLoS One. 2012;7(5):e36246. doi: 10.1371/journal.pone.0036246. Epub 2012 May 4.

39.

Myxobacteria: natural pharmaceutical factories.

Diez J, Martinez JP, Mestres J, Sasse F, Frank R, Meyerhans A.

Microb Cell Fact. 2012 Apr 30;11:52. doi: 10.1186/1475-2859-11-52.

40.

Stable multi-infection of splenocytes during SIV infection--the basis for continuous recombination.

Schultz A, Sopper S, Sauermann U, Meyerhans A, Suspène R.

Retrovirology. 2012 Apr 23;9:31. doi: 10.1186/1742-4690-9-31.

41.

Pathogen prevalence may determine maintenance of antigen-specific T-cell responses in HIV-infected individuals.

Schuetz A, Dirks J, Sester U, Haule A, Elias N, Geldmacher C, Sanga E, Maboko L, Reither K, Hoelscher M, Meyerhans A, Sester M.

AIDS. 2012 Mar 27;26(6):695-700. doi: 10.1097/QAD.0b013e3283519a89.

PMID:
22301414
42.

Monitoring CD27 expression to evaluate Mycobacterium tuberculosis activity in HIV-1 infected individuals in vivo.

Schuetz A, Haule A, Reither K, Ngwenyama N, Rachow A, Meyerhans A, Maboko L, Koup RA, Hoelscher M, Geldmacher C.

PLoS One. 2011;6(11):e27284. doi: 10.1371/journal.pone.0027284. Epub 2011 Nov 7.

43.

Human yeast-specific CD8 T lymphocytes show a nonclassical effector molecule profile.

Breinig T, Scheller N, Glombitza B, Breinig F, Meyerhans A.

Med Microbiol Immunol. 2012 May;201(2):127-36. doi: 10.1007/s00430-011-0213-2. Epub 2011 Sep 25.

PMID:
21947167
44.

A new model for the estimation of cell proliferation dynamics using CFSE data.

Banks HT, Sutton KL, Thompson WC, Bocharov G, Doumic M, Schenkel T, Argilaguet J, Giest S, Peligero C, Meyerhans A.

J Immunol Methods. 2011 Oct 28;373(1-2):143-60. doi: 10.1016/j.jim.2011.08.014. Epub 2011 Aug 24.

45.

Genetic editing of herpes simplex virus 1 and Epstein-Barr herpesvirus genomes by human APOBEC3 cytidine deaminases in culture and in vivo.

Suspène R, Aynaud MM, Koch S, Pasdeloup D, Labetoulle M, Gaertner B, Vartanian JP, Meyerhans A, Wain-Hobson S.

J Virol. 2011 Aug;85(15):7594-602. doi: 10.1128/JVI.00290-11. Epub 2011 Jun 1.

46.

Profound differences of microRNA expression patterns in hepatocytes and hepatoma cell lines commonly used in hepatitis C virus studies.

Ehrhardt M, Leidinger P, Keller A, Baumert T, Díez J, Meese E, Meyerhans A.

Hepatology. 2011 Sep 2;54(3):1112-3. doi: 10.1002/hep.24366. Epub 2011 Jun 27. No abstract available.

PMID:
21503945
47.

Fitness ranking of individual mutants drives patterns of epistatic interactions in HIV-1.

Martínez JP, Bocharov G, Ignatovich A, Reiter J, Dittmar MT, Wain-Hobson S, Meyerhans A.

PLoS One. 2011 Mar 31;6(3):e18375. doi: 10.1371/journal.pone.0018375.

48.

Hepatitis C virus RNA recombination in cell culture.

Reiter J, Pérez-Vilaró G, Scheller N, Mina LB, Díez J, Meyerhans A.

J Hepatol. 2011 Oct;55(4):777-83. doi: 10.1016/j.jhep.2010.12.038. Epub 2011 Feb 18.

PMID:
21334392
49.

Challenges and perspectives for improved management of HIV/Mycobacterium tuberculosis co-infection.

Sester M, Giehl C, McNerney R, Kampmann B, Walzl G, Cuchí P, Wingfield C, Lange C, Migliori GB, Kritski AL, Meyerhans A; European Network for global cooperation in the field of AIDS and TB (EUCO-Net).

Eur Respir J. 2010 Dec;36(6):1242-7. doi: 10.1183/09031936.00040910.

50.

PROCAM-, FRAMINGHAM-, SCORE- and SMART-risk score for predicting cardiovascular morbidity and mortality in patients with overt atherosclerosis.

Uthoff H, Staub D, Socrates T, Meyerhans A, Bundi B, Schmid HP, Frauchiger B.

Vasa. 2010 Nov;39(4):325-33. doi: 10.1024/0301-1526/a000057.

PMID:
21104622

Supplemental Content

Loading ...
Support Center